Drugs / Galicaftor
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05538585 | Sep → Dec 2022 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05530278 | Sep → Nov 2022 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT03540524 | May 2018 → Mar 2019 | cystic fibrosis | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT03128606 | Mar 2017 → Feb 2018 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT03214614 | Nov 2016 → Aug 2017 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT02662452 | Jan → Apr 2016 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04853368 | Sep 2021 → Jun 2023 | cystic fibrosis | AbbVie | Terminated | Mixed Stop: Business |
| Phase 2 | NCT03969888 | Dec 2019 → Jun 2022 | cystic fibrosis | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT03119649 | Mar → Oct 2017 | cystic fibrosis | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 2 | NCT03045523 | Jan → Aug 2017 | cystic fibrosis | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2018-01-02 | Lakefront Biotherapeutics NV | Results Update on progress in cystic fibrosis programs lakefrontbio.com ↗ |
| 2017-11-19 | Lakefront Biotherapeutics NV | Results ALBATROSS with GLPG2222 shows positive clinical results in CF patients lakefrontbio.com ↗
Galapagos NV (Euronext & NASDAQ: GLPG) reports positive topline results from its ALBATROSS Phase 2 study in cystic fibrosis patients with C1 corrector GLPG2222. |
| 2017-06-20 | Lakefront Biotherapeutics NV | Results Galapagos’ R&D Update 2017: rapidly advancing our product candidates lakefrontbio.com ↗
Galapagos reports that Phase 1 results on GLPG2451, GLPG2222 and GLPG2737 showed favorable findings relating to safety and tolerability of the individual components that constitute our current most advanced potential triple combination therapy. |
| 2016-06-15 | Lakefront Biotherapeutics NV | Results Galapagos’ R&D Update 2016 lakefrontbio.com ↗
Galapagos reports that GLPG2222, the first early binding (C1) corrector, passed the safety hurdle in Phase 1 studies in healthy volunteers. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-01-02 | Lakefront Biotherapeutics NV | Update on progress in cystic fibrosis programs lakefrontbio.com ↗ |
| 2017-11-19 | Lakefront Biotherapeutics NV | ALBATROSS with GLPG2222 shows positive clinical results in CF patients lakefrontbio.com ↗ |
| 2017-06-20 | Lakefront Biotherapeutics NV | Galapagos’ R&D Update 2017: rapidly advancing our product candidates lakefrontbio.com ↗ |
| 2017-02-23 | Lakefront Biotherapeutics NV | Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451 lakefrontbio.com ↗ |
| 2017-02-01 | Lakefront Biotherapeutics NV | Galapagos doses first patient with novel CF corrector GLPG2222 lakefrontbio.com ↗ |
| 2016-06-15 | Lakefront Biotherapeutics NV | Galapagos’ R&D Update 2016 lakefrontbio.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Galicaftor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04853368 ↗ |
| Known as | ABBV-2222 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03969888 ↗ |
| Known as | GLPG2222 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03540524 ↗ |
| Action | Activate | “Sweat chloride reductions support on-target enhancement of CFTR activity in subjects with F508del mutation(s).” PMID 31056441 ↗ May 2019 |
| Modality | Small molecule | — CHEMBL4101487 ↗ |
| Route | Oral | “single ascending doses, oral suspension” NCT02662452 ↗ |
| Target | CFTR | “Sweat chloride reductions support on-target enhancement of CFTR activity in subjects with F508del mutation(s).” PMID 31056441 ↗ May 2019 |